AP2001002036A0 - Use of glucose uptake enhancer for reducing apoptosis. - Google Patents

Use of glucose uptake enhancer for reducing apoptosis.

Info

Publication number
AP2001002036A0
AP2001002036A0 APAP/P/2001/002036A AP2001002036A AP2001002036A0 AP 2001002036 A0 AP2001002036 A0 AP 2001002036A0 AP 2001002036 A AP2001002036 A AP 2001002036A AP 2001002036 A0 AP2001002036 A0 AP 2001002036A0
Authority
AP
ARIPO
Prior art keywords
glucose uptake
uptake enhancer
human
cells
reducing apoptosis
Prior art date
Application number
APAP/P/2001/002036A
Other languages
English (en)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of AP2001002036A0 publication Critical patent/AP2001002036A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
APAP/P/2001/002036A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis. AP2001002036A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
AP2001002036A0 true AP2001002036A0 (en) 2001-03-31

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002036A AP2001002036A0 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis.

Country Status (25)

Country Link
EP (2) EP1098639B1 (enExample)
JP (1) JP2002521326A (enExample)
KR (1) KR20010079551A (enExample)
CN (1) CN1310620A (enExample)
AP (1) AP2001002036A0 (enExample)
AT (1) ATE288746T1 (enExample)
AU (1) AU5053799A (enExample)
BG (1) BG105250A (enExample)
BR (1) BR9912117A (enExample)
CA (1) CA2338211A1 (enExample)
DE (1) DE69923687T2 (enExample)
DK (1) DK1098639T3 (enExample)
EA (1) EA200100165A1 (enExample)
ES (1) ES2237929T3 (enExample)
HU (1) HUP0103199A3 (enExample)
ID (1) ID26986A (enExample)
IL (1) IL140664A0 (enExample)
NO (1) NO20010292L (enExample)
OA (1) OA11579A (enExample)
PL (1) PL345627A1 (enExample)
PT (1) PT1098639E (enExample)
SI (1) SI1098639T1 (enExample)
SK (1) SK1012001A3 (enExample)
TR (1) TR200100207T2 (enExample)
WO (1) WO2000004890A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
CN1235543A (zh) * 1996-09-12 1999-11-17 三共株式会社 含有曲格列酮的谷胱甘肽还原酶活性增强剂
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
DE69834508T2 (de) * 1997-11-19 2006-11-23 Takeda Pharmaceutical Co. Ltd. Apoptoseinhibitoren
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
ATE288746T1 (de) 2005-02-15
BR9912117A (pt) 2001-04-10
HUP0103199A2 (hu) 2002-05-29
KR20010079551A (ko) 2001-08-22
EA200100165A1 (ru) 2001-08-27
HUP0103199A3 (en) 2002-08-28
EP1098639B1 (en) 2005-02-09
CA2338211A1 (en) 2000-02-03
EP1098639A1 (en) 2001-05-16
OA11579A (en) 2004-06-01
PT1098639E (pt) 2005-06-30
DK1098639T3 (da) 2005-06-13
IL140664A0 (en) 2002-02-10
NO20010292D0 (no) 2001-01-18
DE69923687T2 (de) 2006-04-06
AU5053799A (en) 2000-02-14
DE69923687D1 (de) 2005-03-17
ID26986A (id) 2001-02-22
NO20010292L (no) 2001-03-08
SK1012001A3 (en) 2001-08-06
HK1037865A1 (en) 2002-02-22
PL345627A1 (en) 2002-01-02
WO2000004890A1 (en) 2000-02-03
EP1516617A2 (en) 2005-03-23
TR200100207T2 (tr) 2001-05-21
SI1098639T1 (enExample) 2005-08-31
CN1310620A (zh) 2001-08-29
ES2237929T3 (es) 2005-08-01
JP2002521326A (ja) 2002-07-16
BG105250A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
GR20010300044T1 (en) Transfected cells and methods for treating diabetes
IL142824A0 (en) Lipoic acid derivatives and their use in treatment of disease
AU6131199A (en) Insertion device for stents and methods for use
PL341300A1 (en) Non-dissolvable compositions for monitoring glucose level in blood
ZA992005B (en) Proton donating actives in absorbent articles.
AU3882599A (en) Vascular graft assemblies and methods for implanting same
MY108685A (en) Absorbing products having integral transverse retaining tab and pocket.
IL129751A0 (en) Bifurcated stent with improved side branch aperture and method of making same
ZA200006576B (en) Methods and compositions for expression of transgenes in plants.
IL138871A0 (en) Flushable diaper and method
ZA200104934B (en) Refastenable and adjustable fastener system for diaper.
IL143435A0 (en) Method for preventing physiological disorders in plants
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
AU6157899A (en) Catheter flush solution and method for its use
AP2001002036A0 (en) Use of glucose uptake enhancer for reducing apoptosis.
AU3913400A (en) Automatic systems and methods for including customs tariffs in e-commerce transactions
GB0210357D0 (en) Methods for regulating blood glucose and appetite suppression in type 2 diabetics
AU1765300A (en) Compositions and methods for reducing or preventing fertilization in fish and birds
HUP0102652A3 (en) Method for treating sugar beet
ZA200003926B (en) Topiramate and related derivatives for treating Schizophrenia.
AR020614A1 (es) Nuevo metodo
WO2001038567A3 (en) Genetic indicators of tobacco consumption
ES1044936Y (es) Guia con efecto dotter para angioplastia y stent directo.